STOCK TITAN

Regencell Bioscience Holdings (RGC) Financials

RGC NASDAQ
FY2026 annual
Revenue Not reported for FY2026
Net Income -$11.7M n/m YoY
EPS (Diluted) -$0.02 n/m YoY
Operating Cash Flow -$7.7M n/m YoY
Market Cap $2.1B as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, FY2026
Price / Book 155x on $13.3M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2026, ended Jun 30, 2026 Reported Currency USD FYE June

Newest figures come from the 20-F for FY2026, filed Oct 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RGC SEC filings page.

This page shows Regencell Bioscience Holdings Limited (RGC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI RGC FY2026

FY2026 shows a research-led business with persistent cash deficits, while financing—not operations—funded its expanded balance sheet.

The FY2026 net loss of $11.7M was larger than its $7.7M operating cash outflow, so accounting losses and cash use diverged rather than moving one-for-one. Operations nevertheless remained cash-consuming, meaning the reported loss did not translate into an equivalent cash drain but still reflected no self-funding engine.

SG&A rose 269.5% to $10.4M in FY2026, making overhead the clearest spending shock. R&D also rose 37.0%, but the sharper SG&A increase indicates spending expansion was concentrated in overhead rather than only scientific work.

FY2026 financing cash flow was $16.9M while operating cash flow was a $7.7M outflow, indicating that added cash came from financing rather than operations. Assets rose 155.9% while liabilities represented 9.4% of assets, so the expanded balance sheet remained equity-heavy. The current ratio was 10.8x, and reported liquidity equaled 22.1 months of annual operating outflow; that describes balance-sheet capacity, not operating self-sufficiency.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Regencell Bioscience Holdings Limited, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

Regencell Bioscience Holdings Limited passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Regencell Bioscience Holdings Limited reported a net loss of $11.7M while operations used $7.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$11.3M
YoYn/m
5Y CAGRn/m

Regencell Bioscience Holdings Limited's EBITDA was -$11.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.

Net Income
-$11.7M
YoYn/m
5Y CAGRn/m

Regencell Bioscience Holdings Limited reported a net loss of $11.7M in fiscal year 2026. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$0.02
YoYn/m
5Y CAGRn/m

Regencell Bioscience Holdings Limited earned -$0.02 per diluted share (EPS) in fiscal year 2026. The change from the prior year is not meaningful, because that figure was zero or negative.

Revenue

Not reported for fiscal year 2026.

Cash & Balance Sheet

Cash & Debt
$14.2M
YoY+486.7%
5Y CAGR+199.0%

Regencell Bioscience Holdings Limited held $14.2M in cash as of fiscal year 2026; no long-term debt figure is on record for that period.

Shares Outstanding
496M
YoY+0.3%
5Y CAGR+5.5%

Regencell Bioscience Holdings Limited had 496M shares outstanding in fiscal year 2026. This represents an increase of 0.3% from the prior year.

Free Cash Flow

Not reported for fiscal year 2026.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Return on Equity
-87.7%
YoY-13.9pp

Regencell Bioscience Holdings Limited's ROE was -87.7% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 13.9 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2026.

Operating Margin

Not reported for fiscal year 2026.

Net Margin

Not reported for fiscal year 2026.

Capital Allocation

R&D Spending
$1.3M
YoY+37.0%
5Y CAGR+24.3%

Regencell Bioscience Holdings Limited invested $1.3M in research and development in fiscal year 2026. This represents an increase of 37.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2026.

Capital Expenditures

Not reported for fiscal year 2026.

RGC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RGC annual income statement
MetricFY2620-FFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
R&D Expenses$1.3M+37.0%$948K-11.1%$1.1M-32.6%$1.6M-37.0%$2.5M+473.1%$438K+13.5%$386K+69.2%$228K
SG&A Expenses$10.4M+269.5%$2.8M-23.1%$3.7M-21.8%$4.7M-8.1%$5.1M+441.4%$943K+121.3%$426K+161.8%$163K
Operating Income-$11.7Mn/m-$3.8Mn/m-$4.7Mn/m-$6.3Mn/m-$7.6Mn/m-$1.4Mn/m-$812Kn/m-$391K
EBITDA-$11.3Mn/m-$3.4Mn/m-$4.0Mn/m-$5.5Mn/m-$6.6Mn/m-$1.4Mn/m-$803KN/A
Net Income-$11.7Mn/m-$3.6Mn/m-$4.3Mn/m-$5.9Mn/m-$7.4Mn/m-$1.3Mn/m-$812Kn/m-$391K
EPS (Basic)-$0.02n/m-$0.01n/m-$0.01n/m-$0.01n/m-$0.02-550.0%$0.00+61.9%$0.00N/A
EPS (Diluted)-$0.02n/m-$0.01n/m-$0.01n/m-$0.01n/m-$0.02n/m$0.00n/m$0.00N/A
Diluted Shares (Avg)495M0.0%494M0.0%494M0.0%494M+1.6%487M+28.1%380M0.0%380MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

RGC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RGC annual balance sheet
MetricFY2620-FFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
Total Assets$14.7M+155.9%$5.8M-31.8%$8.4M-33.1%$12.6M-30.0%$18.0M+5197.6%$340K-33.8%$514KN/A
Current Assets$14.2M+190.1%$4.9M-39.6%$8.1M-30.2%$11.6M-29.3%$16.4M+24499.6%$67K-82.7%$387KN/A
Cash & Equivalents$14.2M+486.7%$2.4M-18.3%$3.0M+89.2%$1.6M-75.6%$6.4M+10700.7%$59K-84.6%$387K+59.0%$243K
Short-Term Investments$0-100.0%$2.5M-50.4%$5.0M-50.0%$10.0M0.0%$10.0Mn/m$0n/m$0n/m$0
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0
Total Liabilities$1.4M+54.2%$895K+307.9%$220K-65.3%$632K-32.6%$938K-78.4%$4.3M+37.1%$3.2MN/A
Current Liabilities$1.3M+99.0%$664K+242.8%$194K-68.1%$607K+5.0%$578K-86.7%$4.3M+37.1%$3.2MN/A
Non-Current Liabilities$59K-74.3%$232K+793.2%$26K+2.1%$25K-92.9%$360Kn/m$0n/m$0N/A
Total Equity$13.3M+174.7%$4.9M-40.9%$8.2M-31.7%$12.0M-29.5%$17.1Mn/m-$4.0Mn/m-$2.7Mn/m-$1.8M
Retained Earnings-$36.9Mn/m-$25.2Mn/m-$21.6Mn/m-$17.3Mn/m-$11.4Mn/m-$4.0Mn/m-$2.7MN/A

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

RGC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RGC annual cash flow statement
MetricFY2620-FFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
Operating Cash Flow-$7.7Mn/m-$3.1Mn/m-$4.0Mn/m-$5.0Mn/m-$5.3Mn/m-$767Kn/m-$727Kn/m-$391K
Depreciation & Amortization$405K+3.0%$393K-47.3%$746K-3.1%$770K-27.3%$1.1M+3901.5%$26K+178.0%$10KN/A
Stock-Based Compensation$3.2M+1217.6%$245K-45.5%$449K-51.3%$923K-66.5%$2.8M+198.9%$923KN/AN/A
Capital ExpendituresN/A$153K+2740.2%$5K-80.4%$27K-96.5%$781KN/A$118KN/A
Free Cash FlowN/A-$3.3Mn/m-$4.0Mn/m-$5.0Mn/m-$6.0MN/A-$844KN/A
Investing Cash Flow$2.5M-6.8%$2.7M-48.8%$5.2M+8789.1%$59Kn/m-$10.8MN/A-$118KN/A
Financing Cash Flow$16.9MN/A$102K-24.2%$135K-99.4%$22.4M+4995.1%$440K-55.5%$988K+105.4%$481K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

RGC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RGC annual financial ratios
MetricFY2620-FFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-F
Return on Equity-87.7%-13.9pp-73.8%-21.4pp-52.3%-3.5pp-48.8%-5.2pp-43.6%N/AN/AN/A
Return on Assets-79.5%-17.2pp-62.3%-11.3pp-51.0%-4.5pp-46.5%-5.2pp-41.3%+354.6pp-395.9%-237.9pp-158.0%N/A
Current Ratio10.77+3.4x7.39-34.5x41.92+22.8x19.15-9.3x28.46+28.4x0.02-0.1x0.12N/A
Liabilities-to-Equity0.10-0.1x0.18+0.2x0.030.0x0.050.0x0.06N/AN/AN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Regencell Bioscience Holdings Limited RGC FY2026 N/A -$11.7M N/A $2.1B —
HUTCHMED (China) Limited HCM FY2025 $548.5M $456.9M 83.3% $2.3B 42/100
Perrigo Company plc PRGO FY2025 $4.3B -$1.4B -33.5% $2.2B 33/100
Prestige Consumer Healthcare Inc. PBH FY2026 $1.1B $190.3M 17.5% $2.4B 62/100
Amylyx Pharmaceuticals, Inc. AMLX FY2025 $0 -$144.7M N/A $3.3B —
Xeris Biopharma Holdings, Inc. XERS FY2025 $291.8M $554K 0.2% $3.1B 45/100

Frequently Asked Questions

No, Regencell Bioscience Holdings Limited (RGC) reported a net loss of $11.7M in fiscal year 2026.

Regencell Bioscience Holdings Limited (RGC) reported diluted earnings per share of -$0.02 for fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Regencell Bioscience Holdings Limited (RGC) had EBITDA of -$11.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

Regencell Bioscience Holdings Limited (RGC) has a return on equity of -87.7% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

Regencell Bioscience Holdings Limited (RGC) recorded an outflow of $7.7M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

Regencell Bioscience Holdings Limited (RGC) had $14.7M in total assets as of fiscal year 2026, including both current and long-term assets.

Regencell Bioscience Holdings Limited (RGC) invested $1.3M in research and development during fiscal year 2026.

Regencell Bioscience Holdings Limited (RGC) had 496M shares outstanding as of fiscal year 2026.

Regencell Bioscience Holdings Limited (RGC) had a current ratio of 10.77 as of fiscal year 2026, which is generally considered healthy.

Regencell Bioscience Holdings Limited (RGC) had a liabilities-to-equity ratio of 0.10 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.

Regencell Bioscience Holdings Limited (RGC) had a return on assets of -79.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

Regencell Bioscience Holdings Limited (RGC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $2.1B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Regencell Bioscience Holdings Limited (RGC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.1B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2026, Regencell Bioscience Holdings Limited (RGC) held $14.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.7M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Regencell Bioscience Holdings Limited (RGC) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Regencell Bioscience Holdings Limited (RGC) reported a net loss of $11.7M while operations used $7.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top